Inogen (INGN) Getting Somewhat Favorable News Coverage, Analysis Shows
Media stories about Inogen (NASDAQ:INGN) have been trending somewhat positive on Sunday, Accern reports. The research firm identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Inogen earned a coverage optimism score of 0.19 on Accern’s scale. Accern also assigned news headlines about the medical technology company an impact score of 45.4910056535365 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Here are some of the news headlines that may have effected Accern Sentiment’s rankings:
- Zacks: Analysts Expect Inogen, Inc (INGN) Will Post Quarterly Sales of $64.14 Million (americanbankingnews.com)
- Zacks: Brokerages Anticipate Inogen, Inc (INGN) to Announce $0.29 EPS (americanbankingnews.com)
- Matt Scribner Sells 2,500 Shares of Inogen, Inc (INGN) Stock (americanbankingnews.com)
- Inogen, Inc (INGN) Stock Rating Reaffirmed by Piper Jaffray Companies (americanbankingnews.com)
- Notable Monday Option Activity: INGN, LVS, TWLO (nasdaq.com)
A number of equities analysts have weighed in on INGN shares. Needham & Company LLC cut their price target on shares of Inogen from $108.00 to $96.00 and set a “strong-buy” rating on the stock in a research note on Thursday, June 8th. J P Morgan Chase & Co increased their price target on shares of Inogen to $102.00 and gave the stock an “overweight” rating in a research note on Monday, June 26th. Zacks Investment Research downgraded shares of Inogen from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 11th. BidaskClub downgraded shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Piper Jaffray Companies reaffirmed a “hold” rating and set a $90.00 price target on shares of Inogen in a research note on Tuesday, September 12th. Four equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $91.33.
Inogen (NASDAQ INGN) opened at 100.87 on Friday. Inogen has a 52 week low of $50.24 and a 52 week high of $105.35. The stock has a market cap of $2.09 billion, a P/E ratio of 87.56 and a beta of 1.02. The stock has a 50 day moving average of $95.95 and a 200-day moving average of $87.38.
Inogen (NASDAQ:INGN) last posted its earnings results on Thursday, August 3rd. The medical technology company reported $0.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.28 by $0.10. The firm had revenue of $64.10 million during the quarter, compared to analysts’ expectations of $59.99 million. Inogen had a net margin of 10.36% and a return on equity of 12.45%. The company’s revenue was up 17.4% compared to the same quarter last year. During the same period in the previous year, the company earned $0.25 earnings per share. Analysts forecast that Inogen will post $1.21 earnings per share for the current year.
In other news, EVP Matt Scribner sold 2,500 shares of the business’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $103.23, for a total value of $258,075.00. Following the completion of the sale, the executive vice president now directly owns 6,964 shares in the company, valued at $718,893.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Raymond Huggenberger sold 14,000 shares of the business’s stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $91.67, for a total transaction of $1,283,380.00. Following the completion of the sale, the director now owns 7,808 shares of the company’s stock, valued at $715,759.36. The disclosure for this sale can be found here. Insiders sold 44,667 shares of company stock valued at $4,170,776 over the last quarter. Corporate insiders own 5.31% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece on another domain, it was copied illegally and reposted in violation of United States & international copyright laws. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/09/17/inogen-ingn-getting-somewhat-favorable-news-coverage-analysis-shows.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Stock Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related stocks with our FREE daily email newsletter.